Madagascar vs Myanmar: Average cost of multi drug-resistant tuberculosis treatment
Madagascar
532 constant 2022 US$
in 2024
Myanmar
468 constant 2022 US$
in 2024
Madagascar rank
77th
Myanmar rank
80th
Average cost of multi drug-resistant tuberculosis treatment over time
- Madagascar
- Myanmar
How they compare
Madagascar currently reports 532 constant 2022 US$ against 468 constant 2022 US$ in Myanmar, a difference of 64 constant 2022 US$.
That makes Madagascar's figure about 1.1 times Myanmar's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Madagascar ahead.
Madagascar ranks 77th and Myanmar ranks 80th of 92 countries.
Across the 2 decades both report, Madagascar averaged higher in 1 and Myanmar in 1.
Head to head by decade
| Decade | Madagascar | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,509 constant 2022 US$ | 1,184 constant 2022 US$ | 324.67 constant 2022 US$ | Madagascar |
| 2020s | 622.2 constant 2022 US$ | 944 constant 2022 US$ | 321.8 constant 2022 US$ | Myanmar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Madagascar or Myanmar?
- Madagascar, at 532 constant 2022 US$ against 468 constant 2022 US$ in Myanmar as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Madagascar and Myanmar?
- 64 constant 2022 US$, with Madagascar ahead.
- How many years of comparable data are there for Madagascar and Myanmar?
- 8 years are reported by both, from 2017 to 2024.
- How do Madagascar and Myanmar rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Madagascar ranks 77th and Myanmar ranks 80th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.